Horizon Therapeutics (HZNP) Tops Q3 EPS by 77c, Raises FY Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Horizon Therapeutics plc Reports Record Third-Quarter 2020 Results; Increases TEPEZZA® Full-Year Net Sales Guidance to Greater Than $800 Million; Increases Full-Year 2020 Net Sales and Adjusted EBITD
November 2, 2020 7:00 AM EST-- Record Third-Quarter 2020 Net Sales of $636.4 Million Increased 90 Percent; Third-Quarter 2020 GAAP Net Income of $292.8 Million; Adjusted EBITDA of $329.8 Million --
-- Quarterly Orphan Segment Net Sales Increased 131 Percent to $534.8 Million, Representing Nearly 85 Percent of Total Company Net Sales --
-- TEPEZZA (teprotumumab-trbw) Third-Quarter 2020 Net Sales of $286.9 Million; Increasing Full-Year 2020 Guidance to Greater Than $800 Million from Greater Than $650 Million; Significantly Increasing Investment in TEPEZZA to Support Continued Strong Growth --
-- KRYSTEXXA® (pegloticase injection) Third-Quarter 2020 Net Sales of $108.5 Million; Increasing Full-Year 2020 Net Sales Guidance to Low... More
